UF startup DNAtrix, a leader in the development of oncolytic viruses for cancer therapy, presented updated safety and efficacy data from the fully-enrolled Phase 2 CAPTIVE / KEYNOTE-192 study of DNX-2401 (tasadenoturev), DNAtrix’s oncolytic adenovirus, followed by pembrolizumab for patients with recurrent glioblastoma. The data demonstrate that the therapy elicits durable clinical activity and has a … Continue reading DNAtrix Presents Positive Results From Study at the 2019 SNO Annual Meeting